Table 1.

Patient demographics, tumor immune characteristics, and tumor-infiltrating lymphocyte expansion

Patient characteristics			Adenocarcinoma caracteristics					TIL first outgrowth from tumor		TIL clinical scale expansione
No.	Age/Gender	Prior chemotherapy regimens	Primary cancer site	Metastasesa	Tumor cells MHC-I expressionb	Tumor-infiltrating CD3+ T cellsc	New cancer cell lines	Fold expansiond	%CD3+CD8+ of live cells	Fold expansion	%CD3+CD8+ of live cells
1	63/M	2	Colon	Liver	n/a	n/a	n/a	12.6	10.5	990	94.0
2	45/M	1	Colon	Liver	n/a	n/a	n/a	19.7	29.1	522	97.0
3	44/F	3	Stomach	Liver, ovary	1+, 5–50%	1–5%	GALM a, b, c, d	31.5	9.0	798	98.0
4	45/F	3	Colon	Liver, retroperitoneum	0–1+, <5%	1–5%	n/a	12.8	10.7	788	98.4
5	57/M	3	Bile duct, intrahepatic	Omentum, liver, ascites	2–3+, >50%	5–50%	BAOM a & b, BAAM	1.1	n/a	n/a	n/a
6	42/M	1	Colon	Retroperitoneum, omentum, lung	2–3+, >50%	0–1%	n/a	Fg	51.0	904	97.4
7	51/M	4	Rectum	Lung, bones	3+, >50%	1–5%	n/a	40.0	59.4	1770	98.0
8	51/M	2	Colon	Lung, liver, bones, penis	2–3+, >50%	1–5%	n/a	1.8	24.9	n/a	n/a
9	57/F	3	Colon	Liver	1+, 5–50%	1–5%	CALM	Fg	10.0	n/a	n/a
10	51/F	1	Colon	Liver, omentum, retroperitoneum, spleen	(L.) 0–1+, <5% (O.) 3+, >50%	(L.) 1–5% (O.) 5–50%	CAPM	Fg	22.7	802	98.0
11	53/F	2	Colon	Abdominal wall, liver, breast	0–1+, <5%	0–1%	CAAWM a, b, c, d	Fg	3.0	n/a	n/a
12	52/F	6	Colon	Lung, liver, omentum, retroperitoneal, pelvis	3+, >50%	1–5%	n/a	60.0	50.8	1517	98.7
13	41/M	5	Colon	Axillary lymph node	1+, <5%	1–5%	n/a	11.0	41.0	>743	97.9
14	37/F	2	Colon	Liver, lung	3+, >50%	1–5%	n/a	47.5	20.8	1995	24.1
15	63/M	2	Stomach	Liver, lung	3+, >50%	1–5%	n/a	46.2	14.4	1454	69.6
16	43/F	2	Bile duct, intrahepatic	Liver, lung	2–3+, >50%	1–5%	n/a	31.7	18.5	802	40.0

NOTE:

^aUnderlined metastases designate the site of TIL harvest, and subsequent columns refer to this tumor.

^bSemi-quantitative measurements of MHC class I performed by immunohistochemistry, with intensity (1+ to 3+) reported in addition to the percent of tumor cells expressing the surface marker (<5%, 5–50%, or >50%).

^cSemi-quantitative measurement, percent of surface of tumor occupied by tumor-infiltrating CD3+ T cells (0–1%, 1–5% or 5–50%).

^dFold expansion cannot be calculated for TIL expanded from tumor fragments (Fg).

^eRapid expansion was obtained in all 16 patients, results shown for samples tested with clinical grade reagents. Patient 1 to 13 had CD8+ T cell enrichment prior to clinical scale expansion.

Abbreviations: BAAM, biliary adenocarcinoma metastatic ascites; BAOM, biliary adenocarcinoma omental metastasis; CAAWM, colon adenocarcinoma abdominal wall metastasis; CALM, colon adenocarcinoma liver metastasis; CAPM, colon adenocarcinoma peritoneal metastasis; Fg, tumor fragments; GALM, gastric adenocarcinoma liver metastasis; MHC-I, MHC class I; n/a, not available.